PEP-3R
Triple GLP-1 / GIP / glucagon receptor agonist
PEP-3R is a triple receptor agonist acting on GLP-1, GIP, and glucagon pathways. Early-phase research reports pronounced fat-loss and metabolic effects that exceed single- and dual-agonist analogues.
- Half-life
- ~6 days
- Administration
- Subcutaneous injection
- Research status
- Phase III clinical trials
What it is
PEP-3R is a next-generation incretin mimetic under investigation. Unlike semaglutide or tirzepatide, it is a triple agonist — activating GLP-1, GIP, and glucagon receptors. That tri-agonist profile drives weight reduction through both appetite suppression and increased energy expenditure.
Research Interests
- Targets multiple pathways for stronger weight-management outcomes
- Suppresses appetite while simultaneously raising caloric burn
- May produce greater body-weight reductions than GLP-1 or dual agonists
- Shows potential across obesity and related metabolic conditions
Safety Profile (Documented in Research)
- GI effects (nausea, slowed digestion) are common during early use
- Glucagon receptor activation may elevate heart rate
- Monitor liver enzymes and cardiovascular markers in research settings
Researcher tips
Fits cutting or fat-loss protocols alongside resistance training and high protein intake
Hydration, electrolytes, and dietary fiber reduce GI distress during titration
Hold each step long enough to read the response before escalating